Monitor for any Form 4 filings from Ting Yang, Lina Deng, or David Lazar indicating share sales. The effective shelf removes the last procedural hurdle to insider selling, which could accelerate price declines. Given the company's lack of active programs and going-concern warning, any selling pressure is likely to be met with limited buying interest.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 20 $2.46entry
- T+1 · 4mo ago +2.44%α +1.60% · $2.52
- T+5 · 4mo ago +6.10%α +6.52% · $2.61
- T+20 · 3mo ago −59.35%α −63.47% · $1.00
- T+60 · 5w ago −2.85%α −7.69% · $2.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics' S-3 registration statement (File No. 333-297088) became effective on July 17, 2026, enabling selling stockholders Ting Yang, Lina Deng, and David Lazar to resell up to 18,864,000 shares (~14.2% of outstanding). The company receives no proceeds and has discontinued all clinical development, with its auditor expressing substantial doubt about going concern. This effectiveness removes the final procedural barrier to insider selling, adding immediate overhang to a stock already under severe fundamental distress.
Key Facts
- S-3 shelf became effective on 2026-07-17, allowing resale of up to 18,864,000 shares by selling stockholders.
- Company discontinued all clinical development of lead candidate Decoy20 and has no active programs.
- Auditor has expressed substantial doubt about Indaptus' ability to continue as a going concern.
- Indaptus will not receive any proceeds from the resale of shares under this shelf.
- The shelf was filed on 2026-06-26 and the EFFECT notice confirms effectiveness 24 days later.
Financial Impact
Potential dilution of ~14.2% of outstanding shares via resale; no proceeds to company. Company has no revenue and is burning cash with going-concern risk.
Risk Factors
- Immediate selling by insider stockholders could drive the stock lower.
- No active pipeline or revenue to support valuation; going-concern risk may materialize.
- Low liquidity may amplify price moves on any selling volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002348 |
| Document: 9999999995-26-002348-index.html | 9999999995-26-002348 |
| Document: 9999999995-26-002348.txt | 9999999995-26-002348 |
Track record
20 reports on INDP
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +25.16% at T+60 after the May 15, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers